If you have an ACS member number, please enter it here so we can link this account to your membership. (optional)

ACS values your privacy. By submitting your information, you are gaining access to C&EN and subscribing to our weekly newsletter. We use the information you provide to make your reading experience better, and we will never sell your data to third party members.

Untitled Document

_____ Brought to you by Tocris _____

New Frontiers in Targeted Protein Degradation and Degrader Development



  April 10, 2019

  11:00 a.m. EDT, 8:00 a.m. PDT, 16:00 BST, 17:00 CEST




The use of heterobifunctional small molecule Degraders (e.g. PROTACs, SNIPERs etc) to elicit targeted protein degradation (TPD) is an area of increasing interest in chemical biology. As tools for basic research, they offer an attractive approach for inducing selective protein knockdown in a reversible and tunable manner, without the requirement for genetic modification to cells. Therapeutically too, this is an area of tremendous current interest, as a potential new approach to tackle the 'undruggable' proteome and overcome common resistance mechanisms to current therapies.

This webinar will provide a practical introduction to the field of Targeted Protein Degradation, discussing design and optimization of Degrader molecules and how structural biology and rational design can shed light on the Degrader development process. The second section of the webinar will present the dTAG platform for target validation. dTAG molecules specifically recognize and degrade FKBP12F36V fusion proteins, presenting a new platform for target validation studies.

Brought to you by:


Key Learning Objectives

  • What are Degraders and what is meant by Targeted Protein Degradation (TPD)
  • Opportunities and challenges for Degrader development
  • Development of Degraders from a medicinal chemistry perspective: application of structural biology and rational design strategies
  • The development and application of the dTAG degradation platform

Who Should Attend

  • Medicinal chemists and chemical biologists with an active or planned Degrader (PROTAC) development program
  • Scientists looking to further understand the exciting field of targeted protein degradation


Behnam Nabet, Ph.D.,
Postdoctoral Research Fellow,
Dana-Farber Cancer Institute
William Farnaby,
Team Leader, Chemical Biology/ Medicinal Chemistry,
Dundee University, in collaboration with Boehringer Ingelheim


Stu Borman,
Contributing Senior Editor,
C&EN Media Group